Resveratrol prevents p53 aggregation in vitro and in breast cancer cells

One potential target for cancer therapeutics is the tumor suppressor p53, which is mutated in more than 50% of malignant tumors. Loss of function (LoF), dominant negative (DN) and gain of function (GoF) mutations in p53 are associated with amyloid aggregation. We tested the potential of resveratrol,...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferraz da Costa, Danielly C., Campos, Nathali P.C., Santos, Ronimara A., Guedes-da-Silva, Francisca Hildemagna, Martins-Dinis, Mafalda Maria D.C., Zanphorlin, Letícia, Ramos, Carlos, Rangel, Luciana P., Silva, Jerson L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6044377/
https://www.ncbi.nlm.nih.gov/pubmed/30018739
http://dx.doi.org/10.18632/oncotarget.25631

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6044377/
https://www.ncbi.nlm.nih.gov/pubmed/30018739
http://dx.doi.org/10.18632/oncotarget.25631

Ejemplares similares